While Adimmune Corp’s production of vaccines is the concern of the company and the Food and Drug Administration, vaccination policy is jointly managed by the Department of Health (DOH) and the Centers for Disease Control (CDC). The government departments that oversee production and use of vaccines are on an equal footing, neither being subordinate to the other, and the relationship between the vaccine maker and the government being one of buyer and seller.
Former health ministers have voiced their support for the government’s swine flu vaccination program — Chen Chien-jen (陳建仁) by volunteering for a flu jab and Twu Shiing-jer (涂醒哲) by saying that he hoped everyone would get vaccinated. The vaccines are supplied by two companies — Adimmune and Novartis — and they do not have the right to be partial to one or the other.
Adimmune chairman Steve Chan (詹啟賢), also a former health minister, has criticized Minister of Health Yaung Chih-liang (楊志良) for being unwilling to publish vaccine test data. This is a question of government and business taking a different approach.
When Novartis was having difficulty supplying enough vaccines to meet demand, the DOH and the CDC had no choice but to approach Adimmune as the only other possible supplier.
Now that both Novartis and Adimmune are able to supply adequate amounts of the vaccine, it is time to shore up public confidence by publishing clinical test data on the two companies’ vaccines. Novartis’ A(H1N1) vaccine test report can be found in the Sept. 11, 2009 and Dec. 31, 2009 issues of the New England Journal of Medicine.
Any adverse reactions following administration of the vaccine should be announced in a timely manner, and statistics should be compiled of mild and severe reactions.
The occurrence of severe reactions should be weighed against the death rate for A(H1N1) in the whole population (six in 100,000). If the disadvantages of immunization outweigh the advantages by a statistically significant margin, then the newly established Food and Drug Administration (FDA) should intervene and investigate. If the FDA finds this task to be beyond its limited capabilities, then it should invite experts from overseas drug administrations to help out.
In 1976, when the US instituted a program for the whole population to be vaccinated against swine flu, there were 743 cases of severe adverse reactions, including 67 deaths. The vaccination program started on Oct. 1 of that year. As severe reactions were reported one after another, and given the fact that the human mortality rate from swine flu was not as high as expected, the program was terminated on Dec. 16. A New York Times opinion piece described the affair as a “sorry debacle.”
Although science and technology are more advanced today than they were then, Adimmune should take what happened 34 years ago as a warning. The company must face the risk of allergic and autoimmune reactions such as death, semiplegia, rheumatoid arthritis and acute facial palsy and publish data about severe reactions so they can be compared with equivalent figures from the US and figures for severe reactions to the Novartis vaccine in Taiwan.
Since 1998, when I was involved in the CDC’s establishment and promotion of the flu vaccination program for people aged 65 and over, I have watched the CDC gradually mature in its efforts to prevent enterovirus and influenza.
This is borne out by public support for the CDC, which has consistently been over 80 percent throughout the past decade.
In the first month of the A(H1N1) vaccination program, which started in November, cancellations of classes and work because of swine flu outbreaks plunged 95 percent, and the number of deaths has not risen from 35. These figures indicate that the immunization policy is a wise one.
In the US, following the failure of the 1976 swine flu immunization program, the vaccine industry reviewed its work under the strengthened supervision of the US CDC, allowing it to emerge from the crisis and start anew.
The same should be done in the case of Adimmune and other vaccine makers in Taiwan. Furthermore, capital owned by political parties should not be invested in the vaccine industry; otherwise it will create a situation where those parties can control national health policy through the DOH.
The spat between Chan and Yaung should serve as a warning.
Mayo Kuo is a pediatrician.
TRANSLATED BY JULIAN CLEGG
Concerns that the US might abandon Taiwan are often overstated. While US President Donald Trump’s handling of Ukraine raised unease in Taiwan, it is crucial to recognize that Taiwan is not Ukraine. Under Trump, the US views Ukraine largely as a European problem, whereas the Indo-Pacific region remains its primary geopolitical focus. Taipei holds immense strategic value for Washington and is unlikely to be treated as a bargaining chip in US-China relations. Trump’s vision of “making America great again” would be directly undermined by any move to abandon Taiwan. Despite the rhetoric of “America First,” the Trump administration understands the necessity of
US President Donald Trump’s challenge to domestic American economic-political priorities, and abroad to the global balance of power, are not a threat to the security of Taiwan. Trump’s success can go far to contain the real threat — the Chinese Communist Party’s (CCP) surge to hegemony — while offering expanded defensive opportunities for Taiwan. In a stunning affirmation of the CCP policy of “forceful reunification,” an obscene euphemism for the invasion of Taiwan and the destruction of its democracy, on March 13, 2024, the People’s Liberation Army’s (PLA) used Chinese social media platforms to show the first-time linkage of three new
If you had a vision of the future where China did not dominate the global car industry, you can kiss those dreams goodbye. That is because US President Donald Trump’s promised 25 percent tariff on auto imports takes an ax to the only bits of the emerging electric vehicle (EV) supply chain that are not already dominated by Beijing. The biggest losers when the levies take effect this week would be Japan and South Korea. They account for one-third of the cars imported into the US, and as much as two-thirds of those imported from outside North America. (Mexico and Canada, while
The military is conducting its annual Han Kuang exercises in phases. The minister of national defense recently said that this year’s scenarios would simulate defending the nation against possible actions the Chinese People’s Liberation Army (PLA) might take in an invasion of Taiwan, making the threat of a speculated Chinese invasion in 2027 a heated agenda item again. That year, also referred to as the “Davidson window,” is named after then-US Indo-Pacific Command Admiral Philip Davidson, who in 2021 warned that Chinese President Xi Jinping (習近平) had instructed the PLA to be ready to invade Taiwan by 2027. Xi in 2017